Purpuromycin

Drug Profile

Purpuromycin

Latest Information Update: 30 Sep 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biosearch Italia
  • Class Antibacterials; Antifungals; Antiprotozoals; Naphthoquinones; Small molecules
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Bacterial infections; Candidiasis; Protozoan infections

Most Recent Events

  • 30 Sep 2005 Vicuron Pharmaceuticals has since been acquired by and merged into Pfizer
  • 11 Jun 2001 No-Development-Reported for Bacterial infections in Italy (Topical)
  • 11 Jun 2001 No-Development-Reported for Candidiasis in Italy (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top